Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS.

Fiche publication

Date publication

juin 2025

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr WESTEEL Virginie

Tous les auteurs :
Gobbini E, Langlais A, Missy P, Chanoine S, Besse B, Souquet PJ, Barlesi F, Audigier-Valette C, Métivier AC, Monnet I, Hureaux J, Jeannin G, Cadranel J, Lagrange A, Tran Q, Morin F, Molinier O, Westeel V, Girard N, Moro-Sibilot D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40532471

Résumé

Most patients with lung cancer have comorbidities at the time of diagnosis. Treatments prescribed for cancer-related symptoms are thus added to drugs for chronic diseases. The impact of comedication on immunotherapy efficacy has been studied in retrospective series, but the results are often biased by the lack of information on the independent prognostic impact of comedication weighted for comorbidities and disease aggressiveness.